SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Eris Jordan, OD, vice president of global clinical and medical affairs at Aurion Biotech, discusses the company’s novel cell therapy for corneal endothelial disease.
The company has opened an investigational new drug application for the treatment, which it plans to launch commercially in Japan next year. The first patients have also been dosed in the U.S. clinical trial investigating the cell therapy, Jordan said.
“I think what’s so unique about our program is the robust amount of clinical data that